TX-KINAXIS
5.3.2024 13:01:37 CET | Business Wire | Press release
Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced collaborations with two prominent non-profit organizations – Women Who Code and Ellen MacArthur Foundation – to accelerate the company’s vision to preserve the planet’s resources and enrich the human experience. The partnerships were announced within the company’s new 2023 Sustainability Report which highlights the latest environmental, social, and governance (ESG) metrics to coincide with annual financial reporting and disclosures.
Kinaxis will work with Women Who Code, whose mission is to empower diverse women to excel in technology careers and the Ellen MacArthur Foundation, which advocates for the creation of a circular economy to eliminate waste and pollution, circulate products and materials, and regenerate nature.
Both organizations are focused on supporting and elevating innovators and changemakers to solve some of the world’s most pressing problems, which mirrors how Kinaxis is approaching solving the complexities of supply chain.
“Both Women Who Code and the Ellen MacArthur Foundation are committed to creating a world where the only limiting factor is your own imagination. We couldn’t be more thrilled to explore ways we can work with them as supply chain resiliency and sustainability take on new levels of importance in our new era of never-ending disruptions,” said John Sicard, president and chief executive officer at Kinaxis. “Our ambition to power the world’s supply chains is a big one and we know we can’t do it all on our own which is why collaborations with likeminded organizations are so critical to helping us advance a circular economy and socially responsible future for all.”
Women Who Code provides engineers, developers, data scientists, architects, designers and other technologists with the tools, resources, and opportunities they need to grow and succeed in their tech related careers. In keeping with the company’s commitment to shaping a more inclusive and equitable future for women in tech, Kinaxis will engage with the organization by ramping up membership recruitment efforts, establishing a new mentorship program and providing resources that spark interest in supply chain careers.
By becoming a Member of the Ellen MacArthur Foundation’s Network, Kinaxis will collaborate with the organization’s extensive network of circular economy leaders and practitioners to advance circular practices in the industry and get involved with groundbreaking research projects designed to drive innovation at scale. Moving away from a ‘take, make, waste’ linear model, the circular economy offers businesses the opportunity to redesign their supply chains to meet these needs, as well as reduce costs and cut greenhouse gas emissions.
Sicard continues: “As the single largest consumer of the Earth’s natural resources – whether it’s the materials used to make something, the resources required to store something, or the emissions expelled to ship something – supply chains are poised to make a significant positive impact, not just because regulations demand it.”
With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands in sectors such as CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies that supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.
More details on the new partnerships and the company’s corporate giving program can be found in the 2023 Sustainability Report.
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305961661/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
